+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 2
Age: 18Years - 75Years
All Genders
ID07463183

Evaluating MK-8690 for Efficacy and Safety in Adults with Moderate to Severe Ulcerative Colitis Using Subcutaneous Injection

Led by Merck Sharp & Dohme LLC · Updated on 2026-10-23

100

Participants Needed

39

Research Sites

60 weeks

Total Duration

AI-Summary

What This Trial Is About

Researchers are evaluating MK-8690 in adults with moderately to severely active ulcerative colitis to determine if it can help achieve clinical remission by Week 12. This phase 2a study compares MK-8690 to a placebo and aims to see if MK-8690 is more effective based on the Modified Mayo Score. Participants will receive subcutaneous injections of MK-8690 or placebo for 12 weeks. Those who do not respond to the initial treatment will receive MK-8690 for another 12 weeks. Responders from either treatment period will have the option to continue MK-8690 for up to approximately 42 additional weeks. During the study, participants will be monitored for clinical remission, response, endoscopic improvement, and mucosal healing using scores like the Modified Mayo Score at Week 12. Safety will be assessed by tracking adverse events throughout the trial, which lasts up to about 12 months. The study involves randomization and triple masking to ensure unbiased results.

CONDITIONS

Brief Title

A Study to Evaluate Efficacy and Safety of MK-8690 in Participants With Moderately to Severely Active Ulcerative Colitis (MK-8690-002)

Research Team

T

Toll Free Number

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here